Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.
about
Regulating mammalian target of rapamycin to tune vaccination-induced CD8(+) T cell responses for tumor immunityCpG Oligonucleotides as Cancer Vaccine AdjuvantsMaterials based tumor immunotherapy vaccinesAdjuvants for peptide-based cancer vaccinesDownregulation of KIF23 suppresses glioma proliferationCarbon nanotubes as vaccine scaffoldsMAGE-C2/CT10 protein expression is an independent predictor of recurrence in prostate cancerTrypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccineA novel human-derived antibody against NY-ESO-1 improves the efficacy of chemotherapySafety and immunogenicity of multimeric-001--a novel universal influenza vaccine.Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses.Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements.Genome-wide analysis of cancer/testis gene expression.Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells.Tumor immunity against a simian virus 40 oncoprotein requires CD8+ T lymphocytes in the effector immune phaseCancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer.Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens.Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.B cell TLRs and induction of immunoglobulin class-switch DNA recombination.Toll-like receptor agonists in cancer therapy.Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy.Bridging innate and adaptive antitumor immunity targeting glycans.NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.Effective inhibition of melanoma tumorigenesis and growth via a new complex vaccine based on NY-ESO-1-alum-polysaccharide-HH2.Outlining novel cellular adjuvant products for therapeutic vaccines against cancer.Split T cell tolerance against a self/tumor antigen: spontaneous CD4+ but not CD8+ T cell responses against p53 in cancer patients and healthy donors.Expression and clinical significance of cancer-testis genes in clear cell renal cell carcinoma.Toll-like receptor agonists: are they good adjuvants?Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients.Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets.TLR-based immune adjuvants.Prognostic and diagnostic value of spontaneous tumor-related antibodiesPitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers.Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.Cancer testis antigens and NY-BR-1 expression in primary breast cancer: prognostic and therapeutic implications.
P2860
Q24610550-8D3730BD-3B5D-4E9A-B0F9-A750DAFCFF08Q26783826-C71ADDB4-9171-48A0-B579-10E6768AF191Q26824135-6594FF7D-AAD0-4596-90E2-8CA5C65C9CA3Q28072236-AB26D940-A7C0-4E3B-8107-701DFEE06E70Q28247603-53B4E9DB-3B5A-4A2E-8B7F-BC5A7F918846Q28392532-208B4CBE-2D06-41F6-ABF9-5C1C21B406E2Q28478930-E4AB4B2C-BAA5-49CC-833E-11B6647CD2A5Q28483146-B9177969-8D79-46EB-BDEC-47111FC69FA2Q28709361-88FA0101-8B85-4460-9A3B-3B59781D2A13Q30412800-3F8F84B2-6560-44A0-924A-53D5F85E7D40Q30667174-732A8F7A-1D0E-4B4E-878E-371D6963B721Q33367582-F54DA5AC-E4C9-45E8-BB76-77C0727A626EQ33393581-2091A1A1-4A16-41AC-B2F2-3D77E57166DAQ33526746-8C00D167-CA15-44F5-B55E-914B3ED386E8Q33558482-7782FFF1-C55F-4B89-9F96-CA4F751037C8Q33582300-EEF7E86C-433B-466F-8B44-219FADA4E318Q33586724-25BA1B72-E77A-473E-94D9-7246748FF1D3Q33779931-7EB6618E-C660-44C7-BFA0-C912AE1F232EQ33841896-823757D2-6CE7-4789-B190-159ECA580024Q33857800-C50E9340-8030-480D-80EB-E5D55AD3322DQ33893517-7CED5661-AFFD-4C5E-B664-A6A8AE5F4825Q33918509-317CAFDC-3230-432B-8354-431C3DABBF86Q33957896-EB41408E-07F4-42D7-9B52-8F1B8384DCFEQ33960021-A9A31AAB-77A7-4F11-8DE2-4B72655448C2Q33987977-DED02660-3D76-4542-8587-9171B983625AQ33994533-F404F78B-E957-4B0E-84BC-A19548AB7B39Q33997622-C11B5BD9-CC26-40C2-9D4D-C248EC7B25AEQ33999909-5F68C228-A5BA-4478-9C38-A81D9237B9CEQ34029148-D3A7C0E7-E734-4915-8740-6E4887979513Q34067537-6A522BC1-8D97-45CE-A54D-D4E7D33D8CBAQ34093600-6EC17147-B244-4F83-801A-6B03146187E7Q34187201-B12279AC-5E30-466D-937D-C56E7835D554Q34343664-D6FACBB9-DA41-4EF5-9310-59744F687BD1Q34400322-D63168A3-9AB4-401F-BF7A-5E5B02B02CC3Q34475795-C05B3225-1D46-4B37-8E77-7AF1163F7DBEQ34508125-00A96AA9-13BC-4C3E-A285-8DB3E8D1451DQ34613585-0DC115C9-E70F-4044-A679-4EC2F8C46BC4Q34619324-FC82073A-46BB-414F-8E98-4258925FC347Q34627677-66D4D56C-6528-4F96-976F-DF1E7824A8F3Q34753747-6161CCF3-9D8C-4583-AB5B-DFCB7C7AE6B1
P2860
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Vaccination with NY-ESO-1 prot ...... T cells through cross-priming.
@ast
Vaccination with NY-ESO-1 prot ...... T cells through cross-priming.
@en
type
label
Vaccination with NY-ESO-1 prot ...... T cells through cross-priming.
@ast
Vaccination with NY-ESO-1 prot ...... T cells through cross-priming.
@en
prefLabel
Vaccination with NY-ESO-1 prot ...... T cells through cross-priming.
@ast
Vaccination with NY-ESO-1 prot ...... T cells through cross-priming.
@en
P2093
P2860
P50
P356
P1476
Vaccination with NY-ESO-1 prot ...... T cells through cross-priming
@en
P2093
Achim A Jungbluth
Angelica Angiulli
Anna Pavlick
Crystal M Cruz
Danila Valmori
David O'Neill
Eric W Hoffmann
Francesca Angiulli
Gerd Ritter
Gregory Mears
P2860
P304
P356
10.1073/PNAS.0703395104
P407
P577
2007-05-15T00:00:00Z